Ts role in malignant hematologic problems.AcknowledgmentsThis operate was supported by the National Natural Science PEG4 linker site Foundation of China (81274142, 30300139), and the Natural Science Foundation of Science and Technology Commission of Shanghai Municipality (11ZR1423400) and theDrug Style, Improvement and Therapy 2015:DovepressDovepressas4s4 combined therapy in gastric and colon Vessel Inhibitors Reagents cancer 21. Lal G, Ash C, Hay K, et al. Suppression of intestinal polyps in Msh2deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 2001;61(16):6131?136. 22. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical concerns. J Natl Cancer Inst. 2002;94(4):252?66. 23. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by precise cyclooxygenase-2 inhibitor, celecoxib, administered during diverse stages of carcinogenesis. Cancer Res. 2000;60(two):293?97. 24. Koki AT, Masferrer JL. Celecoxib: a particular COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9(two Suppl):28?five. 25. Steinbach G, Lynch PM, Phillips RK, et al. The impact of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946?952. 26. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9): 873?84. 27. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a doable prevention and remedy tactic. Int J Clin Pract. 2008;62(three):444?49. 28. Printz C. Celecoxib could avoid lung cancer. Cancer. 2012;118(1):3. 29. Qiu H, Jackson AL, Kilgore JE, et al. JQ1 suppresses tumor growth via downregulating LDHA in ovarian cancer. Oncotarget. 2015;six(9):6915?930. 30. Li Z, Wu C, Wu J, et al. Synergistic antitumor effects of combined deguelin and cisplatin remedy in gastric cancer cells. Oncol Lett. 2014;eight(four):1603?607. 31. Yuan TM, Liang RY, Chueh PJ, Chuang SM. Role of ribophorin II within the response to anticancer drugs in gastric cancer cell lines. Oncol Lett. 2015;9(4):1861?868. 32. Kim J, Kim N, Park JH, et al. The Impact of Helicobacter pylori on Epidermal Development Element Receptor Induced Signal Transduction and the Preventive Impact of Celecoxib in Gastric Cancer Cells. Gut Liver. 2013;7(five):552?59. 33. Wang H, Ke F, Zheng J. Hedgehog-glioma-associated oncogene homolog-1 signaling in colon cancer cells and its part in the celecoxibmediated anti-cancer impact. Oncol Lett. 2014;eight(five):2203?208. 34. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36?six. 35. Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for sufferers with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer. 1995;76(ten):1694?699. 36. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in sophisticated gastric adenocarcinoma: a French intergroup (F ation Francophone de Canc ologie Digestive, F ation Nationale des Centres de Lutte Contre le Cancer, and Groupe Coop ateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520?526. 37. Conroy T, Desseigne F, Ychou M, et al.